CN105259348A - 一种分泌型Sema4C蛋白及其应用 - Google Patents
一种分泌型Sema4C蛋白及其应用 Download PDFInfo
- Publication number
- CN105259348A CN105259348A CN201510699053.1A CN201510699053A CN105259348A CN 105259348 A CN105259348 A CN 105259348A CN 201510699053 A CN201510699053 A CN 201510699053A CN 105259348 A CN105259348 A CN 105259348A
- Authority
- CN
- China
- Prior art keywords
- sema4c
- albumen
- secreting type
- concentration
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003248 secreting effect Effects 0.000 title claims abstract description 75
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 44
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 38
- 101100042271 Mus musculus Sema3b gene Proteins 0.000 title abstract 8
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 72
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 69
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 46
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 19
- 238000012544 monitoring process Methods 0.000 claims abstract description 14
- 239000007788 liquid Substances 0.000 claims description 41
- 210000002966 serum Anatomy 0.000 claims description 30
- 238000001514 detection method Methods 0.000 claims description 28
- 238000002965 ELISA Methods 0.000 claims description 21
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 230000006798 recombination Effects 0.000 claims description 12
- 238000005215 recombination Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 241000283707 Capra Species 0.000 claims description 10
- 229960002685 biotin Drugs 0.000 claims description 9
- 235000020958 biotin Nutrition 0.000 claims description 9
- 239000011616 biotin Substances 0.000 claims description 9
- 238000002372 labelling Methods 0.000 claims description 9
- 239000012160 loading buffer Substances 0.000 claims description 9
- 239000012452 mother liquor Substances 0.000 claims description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 7
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 7
- 229940098773 bovine serum albumin Drugs 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 7
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 7
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 7
- 241000283074 Equus asinus Species 0.000 claims description 6
- 102000013415 peroxidase activity proteins Human genes 0.000 claims description 6
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 6
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims description 5
- 229940005654 nitrite ion Drugs 0.000 claims description 5
- 238000007865 diluting Methods 0.000 claims description 3
- 239000008363 phosphate buffer Substances 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 abstract description 8
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 7
- 239000012528 membrane Substances 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 238000011156 evaluation Methods 0.000 abstract description 4
- 239000000439 tumor marker Substances 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 3
- 238000010882 preoperative diagnosis Methods 0.000 abstract description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 25
- 238000000034 method Methods 0.000 description 20
- 239000000427 antigen Substances 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 11
- 238000012546 transfer Methods 0.000 description 11
- 238000011282 treatment Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 101710199418 Semaphorin-4C Proteins 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 102100027745 Semaphorin-4C Human genes 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 210000005073 lymphatic endothelial cell Anatomy 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 201000008275 breast carcinoma Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000013399 early diagnosis Methods 0.000 description 4
- 102000015694 estrogen receptors Human genes 0.000 description 4
- 108010038795 estrogen receptors Proteins 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 210000001077 lymphatic endothelium Anatomy 0.000 description 4
- 102000003998 progesterone receptors Human genes 0.000 description 4
- 108090000468 progesterone receptors Proteins 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000002798 spectrophotometry method Methods 0.000 description 4
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 3
- 101100310044 Homo sapiens SEMA4C gene Proteins 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 208000019065 cervical carcinoma Diseases 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000012309 immunohistochemistry technique Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 201000000498 stomach carcinoma Diseases 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000001531 bladder carcinoma Diseases 0.000 description 2
- 239000001045 blue dye Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000012113 quantitative test Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 206010029174 Nerve compression Diseases 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 102000014105 Semaphorin Human genes 0.000 description 1
- 108050003978 Semaphorin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000007295 breast benign neoplasm Diseases 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 201000007741 female breast cancer Diseases 0.000 description 1
- 201000002276 female breast carcinoma Diseases 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 208000030776 invasive breast carcinoma Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000011248 postoperative chemotherapy Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
编号 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
A | 3.125 | 3.125 | 3.125 | 3.125 | 3.125 | 3.125 | 3.125 | 3.125 | 3.125 | 3.125 | 3.125 | 3.125 |
B | 6.25 | 6.25 | 6.25 | 6.25 | 6.25 | 6.25 | 6.25 | 6.25 | 6.25 | 6.25 | 6.25 | 6.25 |
C | 12.5 | 12.5 | 12.5 | 12.5 | 12.5 | 12.5 | 12.5 | 12.5 | 12.5 | 12.5 | 12.5 | 12.5 |
D | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
E | 3.125 | 3.125 | 3.125 | 3.125 | 3.125 | 3.125 | 3.125 | 3.125 | 3.125 | 3.125 | 3.125 | 3.125 |
F | 6.25 | 6.25 | 6.25 | 6.25 | 6.25 | 6.25 | 6.25 | 6.25 | 6.25 | 6.25 | 6.25 | 6.25 |
G | 12.5 | 12.5 | 12.5 | 12.5 | 12.5 | 12.5 | 12.5 | 12.5 | 12.5 | 12.5 | 12.5 | 12.5 |
H | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510699053.1A CN105259348B (zh) | 2015-10-21 | 2015-10-21 | 一种分泌型Sema4C蛋白及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510699053.1A CN105259348B (zh) | 2015-10-21 | 2015-10-21 | 一种分泌型Sema4C蛋白及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105259348A true CN105259348A (zh) | 2016-01-20 |
CN105259348B CN105259348B (zh) | 2017-11-17 |
Family
ID=55099114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510699053.1A Active CN105259348B (zh) | 2015-10-21 | 2015-10-21 | 一种分泌型Sema4C蛋白及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105259348B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109557321A (zh) * | 2018-11-30 | 2019-04-02 | 江苏省农业科学院 | 一种鹅催乳素的双抗体夹心elisa检测方法 |
CN112843255A (zh) * | 2021-03-18 | 2021-05-28 | 华中科技大学同济医学院附属同济医院 | Sema4c在制备抗肿瘤药物中的应用 |
CN114045291A (zh) * | 2021-11-01 | 2022-02-15 | 武汉爱博泰克生物科技有限公司 | 重组人Sema4C蛋白、表达载体、宿主细胞以及应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1880452A (zh) * | 2005-06-17 | 2006-12-20 | 中国人民解放军军事医学科学院基础医学研究所 | 人sema 4c基因能够抑制成肌细胞增殖并促进其向肌管分化 |
CN101201359A (zh) * | 2007-12-18 | 2008-06-18 | 浙江大学 | 检测中期因子浓度的elisa试剂盒及其使用方法 |
US20120149594A1 (en) * | 2010-12-10 | 2012-06-14 | Nuclea Biotechnologies, Inc. | Biomarkers for prediction of breast cancer |
-
2015
- 2015-10-21 CN CN201510699053.1A patent/CN105259348B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1880452A (zh) * | 2005-06-17 | 2006-12-20 | 中国人民解放军军事医学科学院基础医学研究所 | 人sema 4c基因能够抑制成肌细胞增殖并促进其向肌管分化 |
CN101201359A (zh) * | 2007-12-18 | 2008-06-18 | 浙江大学 | 检测中期因子浓度的elisa试剂盒及其使用方法 |
US20120149594A1 (en) * | 2010-12-10 | 2012-06-14 | Nuclea Biotechnologies, Inc. | Biomarkers for prediction of breast cancer |
Non-Patent Citations (4)
Title |
---|
GENEBANK: "KJ899036.1", 《GENEBANK》 * |
NCBI: "NM_017789.3", 《NCBI》 * |
WWW.CHEM17.COM: "人臂板蛋白4c(Sema4C)ELISA试剂盒", 《上海润裕生物科技有限公司》 * |
吴海涛: "Sema4C基因在成肌分化过程中的表达、功能及作用机制研究", 《中国博士学位论文全文数据库 基础科学辑》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109557321A (zh) * | 2018-11-30 | 2019-04-02 | 江苏省农业科学院 | 一种鹅催乳素的双抗体夹心elisa检测方法 |
CN112843255A (zh) * | 2021-03-18 | 2021-05-28 | 华中科技大学同济医学院附属同济医院 | Sema4c在制备抗肿瘤药物中的应用 |
CN114045291A (zh) * | 2021-11-01 | 2022-02-15 | 武汉爱博泰克生物科技有限公司 | 重组人Sema4C蛋白、表达载体、宿主细胞以及应用 |
CN114045291B (zh) * | 2021-11-01 | 2022-07-19 | 武汉爱博泰克生物科技有限公司 | 重组人Sema4C蛋白、表达载体、宿主细胞以及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN105259348B (zh) | 2017-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017107974A1 (zh) | 血清psmd4蛋白的检测试剂盒及其检测方法与应用 | |
Nesterova et al. | Autoantibody biomarker opens a new gateway for cancer diagnosis | |
Zhang et al. | Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma | |
CN104136630B (zh) | 诊断和预示乳腺癌的标志物 | |
CN110187108A (zh) | 一种用于早期食管癌筛查的自身抗体联合检测elisa试剂盒 | |
Nakagawa et al. | Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma. | |
CN102445539B (zh) | 一种应用于肝癌的早期筛查和诊断的抗体芯片及试剂盒 | |
CN101210927B (zh) | 一种诊断***癌的试剂盒 | |
Degen et al. | Tenascin‐W, a new marker of cancer stroma, is elevated in sera of colon and breast cancer patients | |
CN110187109A (zh) | 一种用于贲门腺癌早期筛查的自身抗体联合检测elisa试剂盒 | |
CN102043058A (zh) | 用于预测肿瘤的乙酰金刚烷胺的检测试剂盒 | |
CN104155457B (zh) | 一种结直肠癌相关“多肽-蛋白组合式标志物”检测试剂盒 | |
CN105259348A (zh) | 一种分泌型Sema4C蛋白及其应用 | |
CN110187111B (zh) | 一种用于早期贲门癌筛查elisa试剂盒 | |
CN106153934B (zh) | 一种高效定量检测高尔基体73的试剂盒 | |
Xu et al. | Combined detection of CA19-9 and B7-H4 in the diagnosis and prognosis of pancreatic cancer | |
CN107422125A (zh) | 与肌层浸润性膀胱癌相关的尿液蛋白质标志物 | |
WO2018036435A1 (zh) | 杂交瘤细胞株scca1及其分泌的单克隆抗体和应用 | |
CN104730249A (zh) | 一种检测人附睾分泌蛋白4的酶联免疫试剂盒 | |
EP3640644B1 (en) | Target marker gp73 for detecting steatohepatitis and detection application method | |
KR20120116518A (ko) | 폐암 조기 진단용 XAGE-1a 마커 및 이의 용도 | |
CN102175850A (zh) | 检测肿瘤标志物内皮细胞特异性分子-1的elisa试剂盒 | |
CN205910194U (zh) | 一种同步联合定量检测不同分子形式人中性粒细胞脂质运载蛋白的免疫层析装置 | |
CN104316695B (zh) | 用于检测肝癌与肝硬化相关多肽-蛋白组合式标志物的双抗体夹心试剂盒 | |
CN115372618A (zh) | 一种检测蛋白标志物水平的试剂在制备用于评估肿瘤治疗效果的诊断产品中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180316 Address after: 430000 room B1, room B1, No. 666 Biological Innovation Park, Wuhan New Technology Development Zone, East Lake New Technology Development Zone, Hubei Patentee after: WUHAN KAIDEWEISI BIOTECHNOLOGY CO.,LTD. Address before: 519031 Guangdong city of Zhuhai province Hengqin Baoxing Road No. 118 Building 1 room 219-257 Patentee before: ZHUHAI YAMA BIOENGINEERING Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200205 Address after: 430022 1095 Liberation Road, Wuhan, Hubei Patentee after: Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology Address before: 430000 room B1, room B1, No. 666 Biological Innovation Park, Wuhan New Technology Development Zone, East Lake New Technology Development Zone, Hubei Patentee before: WUHAN KAIDEWEISI BIOTECHNOLOGY CO.,LTD. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201104 Address after: 430000 room B1, room B1, No. 666 Biological Innovation Park, Wuhan New Technology Development Zone, East Lake New Technology Development Zone, Hubei Patentee after: WUHAN KAIDEWEISI BIOTECHNOLOGY CO.,LTD. Address before: 430022 1095 Liberation Road, Wuhan, Hubei Patentee before: Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology |
|
TR01 | Transfer of patent right |